Clinical validation Leverage their ongoing randomized controlled trial funded by MTEC for Seraph 100 to position the company as a proven solution provider in sepsis and wound infection-related blood purification, enabling co-sponsorship or advisory roles with hospitals seeking evidence-backed therapies.

Oncology expansion Explore partnerships around the oncology initiative with Trusted Health Advisors to integrate blood filtration strategies in metastatic cancer care, offering a complementary modality to existing oncology pipelines and creating cross-sell opportunities to cancer centers.

Executive leadership Engage with the new CEO and senior leadership to align on targeted clinics and regions, proposing nationwide pilot programs for Seraph 100 in critical care units, leveraging their recent leadership appointment to accelerate contract discussions.

Funding and grants Highlight continued funding avenues and Edison Award recognition to secure hospital grants and philanthropic funding for adoption, while proposing reimbursement strategy collaborations with payers to facilitate uptake in sepsis and COVID-19 related therapies.

Strategic partnerships Position ExThera as a partner for hospital systems and biopharma manufacturers needing extracorporeal filtration capabilities, proposing joint development, OEM, or research collaborations to expand Seraph 100 and ONCObind product reach.